WO2015063604A3 - BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF - Google Patents

BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF Download PDF

Info

Publication number
WO2015063604A3
WO2015063604A3 PCT/IB2014/002979 IB2014002979W WO2015063604A3 WO 2015063604 A3 WO2015063604 A3 WO 2015063604A3 IB 2014002979 W IB2014002979 W IB 2014002979W WO 2015063604 A3 WO2015063604 A3 WO 2015063604A3
Authority
WO
WIPO (PCT)
Prior art keywords
ifnβ
therapeutic responsiveness
biomarkers predictive
biomarkers
predictive
Prior art date
Application number
PCT/IB2014/002979
Other languages
French (fr)
Other versions
WO2015063604A2 (en
Inventor
Luisa IMBERTI
Federico SERANA
Ruggero CAPRA
Original Assignee
Imberti Luisa
Serana Federico
Capra Ruggero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imberti Luisa, Serana Federico, Capra Ruggero filed Critical Imberti Luisa
Publication of WO2015063604A2 publication Critical patent/WO2015063604A2/en
Publication of WO2015063604A3 publication Critical patent/WO2015063604A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods, assays and kits for the identification, assessment and/or treatment of a subject having multiple sclerosis (MS) are disclosed.
PCT/IB2014/002979 2013-11-01 2014-10-31 BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF WO2015063604A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899126P 2013-11-01 2013-11-01
US61/899,126 2013-11-01

Publications (2)

Publication Number Publication Date
WO2015063604A2 WO2015063604A2 (en) 2015-05-07
WO2015063604A3 true WO2015063604A3 (en) 2015-09-24

Family

ID=52630402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/002979 WO2015063604A2 (en) 2013-11-01 2014-10-31 BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF

Country Status (1)

Country Link
WO (1) WO2015063604A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3478364A4 (en) 2016-07-01 2019-10-23 Dignity Health Diagnostic or predictor of relapsing remitting multiple sclerosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988175A1 (en) * 2007-05-03 2008-11-05 Bayer Schering Pharma Aktiengesellschaft Predictive RNA profiles
WO2010033624A1 (en) * 2008-09-16 2010-03-25 Bayer Healthcare Llc Interferon response in clinical samples (iris)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE69326967T2 (en) 1992-01-17 2000-06-15 Lakowicz Joseph R Phase modulation energy transfer fluoroimmunoassay
EP0678122B1 (en) 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
EP0682529B2 (en) 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP3150590B1 (en) 2011-02-07 2019-10-16 Biogen MA Inc. S1p modulating agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988175A1 (en) * 2007-05-03 2008-11-05 Bayer Schering Pharma Aktiengesellschaft Predictive RNA profiles
WO2010033624A1 (en) * 2008-09-16 2010-03-25 Bayer Healthcare Llc Interferon response in clinical samples (iris)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GILLI F ET AL: "Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1", MULTIPLE SCLEROSIS JOURNAL (MSJ), SAGE PUBLICATIONS, BASINGSTOKE, GB, vol. 12, no. 1, 1 February 2006 (2006-02-01), pages 47 - 57, XP008102629, ISSN: 1352-4585, DOI: 10.1191/135248506MS1245OA *
VALLITTU A-M ET AL: "MxA protein assay for optimal monitoring of IFN-[beta] bioactivity in the treatment of MS patients", ACTA NEUROLOGICA SCANDINAVICA, MUNKSGAARD, COPENHAGEN, DK, vol. 118, no. 1, 1 July 2008 (2008-07-01), pages 12 - 17, XP009167949, ISSN: 0001-6314, [retrieved on 20071213], DOI: 10.1111/J.1600-0404.2007.00968.X *
WEINSTOCK-GUTTMAN ET AL: "Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 182, no. 1-2, 2 January 2007 (2007-01-02), pages 236 - 239, XP005819512, ISSN: 0165-5728, DOI: 10.1016/J.JNEUROIM.2006.10.011 *

Also Published As

Publication number Publication date
WO2015063604A2 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
EP3446102A4 (en) Methods, systems and kits for in-pen assays
WO2015061634A3 (en) Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
EP3637001A4 (en) Dual-purpose circulating purifier
WO2015134121A3 (en) Negative selection and stringency modulation in continuous evolution systems
WO2015051169A3 (en) Polynucleotide molecules and uses thereof
EP3411720A4 (en) Diagnostic and prognostic methods for cardiovascular diseases and events
WO2015024876A3 (en) Screening method
WO2015184061A3 (en) Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response
MX2020010947A (en) Methods of treating alzheimer's disease.
MA50638A (en) BIOMARKERS ASSOCIATED WITH INTERLEUKIN-33 (IL-33) MEDIA DISEASES AND THEIR USES
WO2015165779A3 (en) Small ncrnas as biomarkers
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
MX2018001353A (en) Water dispersible assays.
EP3690063A3 (en) Diagnosis of lung cancer
MX2015010174A (en) Diagnostic tools to predict onset of preeclampsia.
WO2016057367A8 (en) Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
WO2014140911A3 (en) Diagnostic and therapeutic methods relating to microrna-144
IL240129B (en) Methods and kits for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic -based treatment
EP3517964A3 (en) New markers for the assessment of the risk for development of a cardiovascular disorder
IL255243A0 (en) Biomarkers for determining the clinical response to cell therapy
WO2014008273A3 (en) Methods for treating, diagnosing and/or monitoring progression of oxo associated states
WO2015063604A3 (en) BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
WO2015013233A3 (en) Methods and compositions for the treatment and diagnosis of bladder cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14843179

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14843179

Country of ref document: EP

Kind code of ref document: A2